Literature DB >> 18053737

The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma.

Apostolos Nakas1, Antonio E Martin Ucar, John G Edwards, David A Waller.   

Abstract

OBJECTIVE: Extrapleural pneumonectomy (EPP) has high mortality and morbidity; radical pleurectomy decortication (P/D) carries less mortality but still significant morbidity. This surgery is not suitable for many patients with malignant pleural mesothelioma (MPM) for whom video assisted thoracic surgery (VATS) offers a minimally invasive alternative. We aimed to assess the role of VATS decortication for MPM.
METHODS: Over a 9-year period 208 patients underwent therapeutic surgery for MPM in our unit. One hundred and twelve of the patients underwent EPP, 29 had a P/D and 67 had VATS decortication. Sixty-three of the 208 patients (EPP n=13, P/D n=8 and VATS decortication n=42) were 65 years of age or older at the time of the operation (57 males and 6 females, age 70 (65-80) years). In this group we analyzed perioperative morbidity and mortality and long-term survival data using the Kaplan-Meier method.
RESULTS: Postoperative stay and 30-day mortality was significantly lower for VATS P/D than for EPP (14.3 days vs 36.6 days, p<0.05 and mortality 7.1% vs 23%, respectively). There was no significant difference in the overall mean survival between the two groups (11.5 months for EPP and 14 months for VATS P/D, p=0.6).
CONCLUSION: VATS decortication should be considered in the therapeutic strategy for MPM.

Entities:  

Mesh:

Year:  2007        PMID: 18053737     DOI: 10.1016/j.ejcts.2007.09.039

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  13 in total

Review 1.  A systematic review of lung-sparing extirpative surgery for pleural mesothelioma.

Authors:  Elaine Teh; Francesca Fiorentino; Carol Tan; Tom Treasure
Journal:  J R Soc Med       Date:  2011-02       Impact factor: 5.344

2.  [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma].

Authors:  A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Pe'choux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-10

3.  Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery.

Authors:  Marjorie G Zauderer; Lee M Krug
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 4.  Extended pleurectomy decortication: the current role.

Authors:  Rocco Bilancia; Marco Nardini; David A Waller
Journal:  Transl Lung Cancer Res       Date:  2018-10

5.  Surgical controversies in mesothelioma: MesoVATS addresses the role of surgical debulking.

Authors:  Chuong D Hoang
Journal:  Transl Lung Cancer Res       Date:  2016-02

Review 6.  Management of malignant pleural mesothelioma-The European experience.

Authors:  Isabelle Opitz
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

Review 7.  Randomized controlled trials in malignant pleural mesothelioma surgery-mistakes made and lessons learned.

Authors:  David A Waller; Alan G Dawson
Journal:  Ann Transl Med       Date:  2017-06

8.  The evolution of multimodality therapy for malignant pleural mesothelioma.

Authors:  Marjorie G Zauderer; Lee M Krug
Journal:  Curr Treat Options Oncol       Date:  2011-06

Review 9.  Current surgical strategies for malignant pleural mesothelioma.

Authors:  Teruhisa Takuwa; Seiki Hasegawa
Journal:  Surg Today       Date:  2015-11-21       Impact factor: 2.549

Review 10.  Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health.

Authors:  Volker Neumann; Stefan Löseke; Dennis Nowak; Felix J F Herth; Andrea Tannapfel
Journal:  Dtsch Arztebl Int       Date:  2013-05-03       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.